The Motley Fool··Prosper Junior BakinyEli Lilly's Weight-Loss Dominance Faces Pipeline Challengers, But Lead Remains Secure
Eli Lilly dominates weight-loss pharmaceuticals with 45% 2025 revenue growth, maintaining market lead despite competitor advances due to years-long regulatory timelines.
LLYNVORHHBYREGNclinical trialsweight loss drugs